Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02734004
Title A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

stomach cancer

breast cancer

ovarian cancer

lung small cell carcinoma

Therapies

Durvalumab + Olaparib

Bevacizumab + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Newnan Georgia 30265 United States Details
Research Site Towson Maryland 21204 United States Details
Research Site Boston Massachusetts 02114 United States Details
Research Site Detroit Michigan 48202 United States Details
Research Site Saint Louis Missouri 63110 United States Details
Research Site Hilliard Ohio 43026 United States Details
Research Site Philadelphia Pennsylvania 19104 United States Details
Research Site Bordeaux 33076 France Details
Research Site Caen Cedex 05 14076 France Details
Research Site Clermont Ferrand cedex 01 63011 France Details
Research Site Dijon cedex 21079 France Details
Research Site Marseille CEDEX 5 13385 France Details
Research Site Nantes 44202 France Details
Research Site Paris cedex 14 75014 France Details
Research Site Pierre Benit Cedex 69495 France Details
Research Site Toulouse Cedex 9 31059 France Details
Research Site Villejuif Cedex 94805 France Details
Research Site Haifa 91096 Israel Details
Research Site Jerusalem 91031 Israel Details
Research Site Petah Tikva 49100 Israel Details
Research Site Ramat Gan 5265601 Israel Details
Research Site Tel Aviv 6423906 Israel Details
Research Site Goyang-si 10408 Korea, Republic of Details
Research Site Seongnam-si 13620 Korea, Republic of Details
Research Site Seoul 03080 Korea, Republic of Details
Research Site Seoul 03722 Korea, Republic of Details
Research Site Seoul 05505 Korea, Republic of Details
Research Site Seoul 06273 Korea, Republic of Details
Research Site Seoul 06591 Korea, Republic of Details
Research Site Seoul 135-710 Korea, Republic of Details
Research Site Amsterdam 1066 CX Netherlands Details
Research Site Amsterdam 1081 HV Netherlands Details
Research Site Maastricht 6229 HX Netherlands Details
Research Site Nijmegen 6525 GA Netherlands Details
Research Site Rotterdam 3075 EA Netherlands Details
Research Site Utrecht 3584 CX Netherlands Details
Research Site Chur CH-7000 Switzerland Details
Research Site Lausanne 1011 Switzerland Details
Research Site Cambridge CB2 0QQ United Kingdom Details
Research Site Dundee DD1 9SY United Kingdom Details
Research Site Glasgow G12 0YN United Kingdom Details
Research Site Greater London SW3 6JJ United Kingdom Details
Research Site London NW1 2PG United Kingdom Details
Research Site London SE1 9RY United Kingdom Details
Research Site Manchester M20 4BX United Kingdom Details
Research Site Newcastle Upon Tyne NE7 7DN United Kingdom Details
Research Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field